| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.68M | 24.38M | 24.75M | 23.85M | 47.39M | 42.68M |
| Gross Profit | 10.58M | 10.71M | 11.05M | 11.64M | 19.02M | 20.56M |
| EBITDA | -14.01M | -45.89M | -31.92M | -27.30M | -15.72M | -12.30M |
| Net Income | -21.32M | -53.95M | -37.66M | -32.90M | -24.83M | -21.82M |
Balance Sheet | ||||||
| Total Assets | 33.85M | 36.13M | 43.43M | 68.84M | 67.17M | 82.81M |
| Cash, Cash Equivalents and Short-Term Investments | 8.50M | 13.24M | 19.28M | 16.99M | 30.39M | 39.15M |
| Total Debt | 28.24M | 24.74M | 23.95M | 39.40M | 23.24M | 52.31M |
| Total Liabilities | 75.69M | 82.39M | 82.03M | 73.87M | 53.65M | 61.98M |
| Stockholders Equity | -41.84M | -46.26M | -38.60M | -5.03M | 13.52M | 20.83M |
Cash Flow | ||||||
| Free Cash Flow | -33.27M | -23.31M | -22.11M | -21.97M | -15.99M | -14.07M |
| Operating Cash Flow | -32.79M | -22.66M | -21.76M | -21.43M | -15.62M | -13.44M |
| Investing Cash Flow | -1.03M | -474.00K | 14.21M | -540.00K | -369.00K | -640.00K |
| Financing Cash Flow | 24.14M | 17.09M | 9.84M | 9.00M | 6.71M | 51.02M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $37.76M | ― | ― | ― | -5.22% | 82.06% | |
42 Neutral | $37.61M | ― | -90.56% | ― | ― | 68.13% | |
41 Neutral | $32.41M | -0.90 | -312.77% | ― | ― | 61.18% | |
41 Neutral | $34.89M | -4.70 | -90.87% | ― | 24.95% | 61.65% | |
40 Underperform | $24.78M | -0.54 | ― | ― | 1689.52% | 66.05% | |
32 Underperform | $204.83M | ― | ― | ― | ― | 22.94% |
On October 10, 2025, Elutia Inc. announced the election of Guido J. Neels to its Board of Directors, effective October 9, 2025, and his appointment to the Audit Committee. This move follows the resignations of board members Maybelle Jordan and W. Matthew Zuga, effective October 8, 2025. Neels, with over 40 years of experience in the medical technology sector, is expected to provide valuable insights as Elutia focuses on leveraging its drug-eluting biomatrix technology to build shareholder value, particularly after its recent EluPro divestiture.
The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
On October 1, 2025, Elutia Inc. announced the completion of the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million. This strategic divestiture allows Elutia to concentrate on advancing its NXT-41x biomatrix platform, which targets reconstruction infections post-mastectomy. The sale strengthens Elutia’s financial position, enabling the company to fully fund the development and launch of NXT-41x, a product poised to capture a significant share of the $1.5 billion U.S. market for breast reconstruction biologics. The transaction also included a non-competition agreement and transitional support services to ensure a smooth transfer of the CIED Business assets.
The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
On September 8, 2025, Elutia Inc. entered into an agreement to sell its cardiac implantable electronic device business to Boston Scientific Corporation for $88 million. This transaction is expected to close in the fourth quarter of 2025 and will allow Elutia to focus on its drug-eluting biomatrix solutions in breast reconstruction, strengthen its financial position, and eliminate outstanding debt. The sale marks a strategic shift for Elutia, enabling it to advance its SimpliDerm franchise and drug-eluting pipeline without shareholder dilution, thereby enhancing long-term shareholder value.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
The recent earnings call for Aziyo Biologics, Inc. Class A was marked by a positive sentiment, underscored by significant growth and successful product launches, particularly with EluPro. The company reported improved gross margins and progress in litigation settlements, although challenges persist with SimpliDerm’s performance and ongoing litigation issues.
On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Elutia Inc., a pioneer in drug-eluting biomatrix technologies, focuses on developing and commercializing products that enhance compatibility between medical devices and patients, primarily in the healthcare sector. The company is known for its innovative solutions aimed at improving patient outcomes.